Section Arrow
Quote
PCRX.NASDAQ
- Pacira BioSciences
Quotes are at least 15-min delayed:2025/07/05 14:27 EDT
Last
 23.22
+0.01 (+0.04%)
Day High 
23.395 
Prev. Close
23.21 
1-M High
27.42 
Volume 
202.32K 
Bid
20.02
Ask
26.75
Day Low
23.01 
Open
23.3 
1-M Low
22.82 
Market Cap 
1.07B 
Currency USD 
P/E 12.73 
%Yield -- 
10-SMA 23.92 
20-SMA 24.55 
50-SMA 25.3 
52-W High 27.64 
52-W Low 11.164 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.24/3.67
Enterprise Value
1.50B
Balance Sheet
Book Value Per Share
17.25
Cash Flow
Cash Flow Yield
0.16
Income Statement
Total Revenue
700.97M
Operating Revenue Per Share
14.38
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands0.5387+0.0535+11.03%-- 
RGCRegencell Bioscience Holdings Limited22.99+12.63+121.91%-- 
CGCCanopy Growth Corp1.28+0.09+7.56%-- 
IXHLIncannex Healthcare0.2094+0.0025+1.21%-- 
HLNHaleon plc10.25-0.01-0.10%23.95PE
Quotes are at least 15-min delayed：2025/07/05 14:27 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.